Overview
- Comprehensively covers the multiplicity and diversity of mechanisms underlying resistance to the currently approved drugs, both tyrosine kinase inhibitors and monoclonal antibodies, that specifically inhibit growth factor receptors playing driver or survival functions in cancer
- Examines specific targets and the cognate drugs
- Evaluates molecular modes of innate and evolving resistance
Part of the book series: Resistance to Targeted Anti-Cancer Therapeutics (RTACT, volume 15)
Buy print copy
About this book
This volume comprehensively covers the multiplicity and diversity of mechanisms underlying patient resistance to currently approved anti-cancer drugs, including tyrosine kinase inhibitors and monoclonal antibodies, blockers of growth factor receptors and their downstream pathways, which play essential functions in cancer progression. Each chapter will cover a specific group of targets and the cognate drugs, along with molecular modes of innate and evolving resistance.
Similar content being viewed by others
Keywords
Table of contents (9 chapters)
Editors and Affiliations
About the editors
Bibliographic Information
Book Title: Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways
Editors: Yosef Yarden, Moshe Elkabets
Series Title: Resistance to Targeted Anti-Cancer Therapeutics
DOI: https://doi.org/10.1007/978-3-319-67932-7
Publisher: Springer Cham
eBook Packages: Biomedical and Life Sciences, Biomedical and Life Sciences (R0)
Copyright Information: Springer International Publishing AG, part of Springer Nature 2018
Hardcover ISBN: 978-3-319-67930-3Published: 10 April 2018
Softcover ISBN: 978-3-030-09817-9Published: 02 February 2019
eBook ISBN: 978-3-319-67932-7Published: 28 March 2018
Series ISSN: 2196-5501
Series E-ISSN: 2196-551X
Edition Number: 1
Number of Pages: XX, 242
Number of Illustrations: 22 illustrations in colour
Topics: Cancer Research